Sclerostin in Mineralized Matrices and van Buchem Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sclerostin is an inhibitor of bone formation expressed by osteocytes. We hypothesized that sclerostin is expressed by cells of the same origin and also embedded within mineralized matrices. In this study, we analyzed (a) sclerostin expression using immunohistochemistry, (b) whether the genomic defect in individuals with van Buchem disease (VBD) was associated with the absence of sclerostin expression, and (c) whether this was associated with hypercementosis. Sclerostin was expressed by cementocytes in mouse and human teeth and by mineralized hypertrophic chondrocytes in the human growth plate. In individuals with VBD, sclerostin expression was absent or strongly decreased in osteocytes and cementocytes. This was associated with increased bone formation, but no overt changes in cementum thickness. In conclusion, sclerostin is expressed by all 3 terminally differentiated cell types embedded within mineralized matrices: osteocytes, cementocytes, and hypertrophic chondrocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 2×
“We and others have previously shown that sclerostin inhibits (BMPstimulated) bone formation by antagonizing canonical Wnt signaling (van Bezooijen et al., 2004, 2007, 2008; Li et al., 2005; Semenov et al., 2005; Ellies et al., 2006; Semenov and He, 2006).”
BackgroundIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 3×
“…generalized osteo sclerosis due to increased osteoblastic activity without any evidence of hor monal abnormalities (van Buchem et al., 1955; Truswell, 1958; Epstein et al., 1979; Balemans et al., 2001, 2002; Brunkow et al., 2001; StaehlingHampton et al., 2002; and our own unpublished observations).”
BackgroundSelf-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 3×
“…generalized osteo sclerosis due to increased osteoblastic activity without any evidence of hor monal abnormalities (van Buchem et al., 1955; Truswell, 1958; Epstein et al., 1979; Balemans et al., 2001, 2002; Brunkow et al., 2001; StaehlingHampton et al., 2002; and our own unpublished observations).”
BackgroundSelf-citationSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Self-citationSOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 3×
“Persons with VBD have a 52kb homozygous deletion 35 kb downstream of the SOST gene believed to be responsible for sclerostin deficiency (Balemans et al., 2002; StaehlingHampton et al., 2002).”
BackgroundSelf-citationGenomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442 · cited 3×
“In genetic models of mice with sclerostin overexpression and deficiency, scle rostin affected bone mass by inhibiting osteoblastic bone formation (Winkler et al., 2003; Loots et al., 2005; Li et al., 2008).”
Background
Cited by
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Self-citation
Metadata
- Authors
- van Bezooijen, R. L., Bronckers, A. L., Gortzak, R. A., Hogendoorn, P. C. W., van der Wee-Pals, L., Balemans, W., Oostenbroek, H. J., Van Hul, W., Hamersma, H., Dikkers, F. G., Hamdy, N. A. T., Papapoulos, S. E., & Löwik, C. W. G. M.
- Venue
- Journal of Dental Research
- Publisher
- SAGE Publications
- Published
- 2009-06
- Volume
- 88
- Issue
- 6
- Pages
- 569-574
- ISSN
- 0022-0345 (ISSN-L)
- 1544-0591
- OpenAlex
- W2138749227
- Cited by
- 138
- References
- 7
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sclerostin in Mineralized Matrices and van Buchem Disease. https://app.cochat.ai/papers/10.1177/0022034509338340
- The paper
- van Bezooijen, R. L., Bronckers, A. L., Gortzak, R. A., Hogendoorn, P. C. W., van der Wee-Pals, L., Balemans, W., Oostenbroek, H. J., Van Hul, W., Hamersma, H., Dikkers, F. G., Hamdy, N. A. T., Papapoulos, S. E., & Löwik, C. W. G. M. (2009). Sclerostin in Mineralized Matrices and van Buchem Disease. Journal of Dental Research. https://doi.org/10.1177/0022034509338340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.